Insider trade

CEO exercised or converted 107K ROIV derivative securities

Traded Oct 7, 2025 · Filed Oct 9, 2025

Roivant SciencesROIV

107K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 7, 2025
Reporting period: Not applicable
Filed with the SEC: Oct 9, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-037740

Filed / recorded

Oct 9, 2025, 5:00 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Eric Venker

Relationship

Officer

Officer title

President & Immunovant CEO

Security

Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Oct 7, 2025

Transaction code

M

Shares / units

107,131

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

128,295

Ownership form

Direct

Amendment

No

Footnotes from the filing

Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.

Around the same time

200KShares · @ $3.85

11mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$4.04M of Roivant Sciences

Scheduled in advance11mo ago

200KDerivative units · @ $20.22

11mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record